

**RECENTLY RELEASED CORONAVIRUS RELATED ARTICLES AND BLOGS ACCORDING
DISEASE APPROACH. October 2020**

Warning: Disseminating results by press release — instead of via peer-reviewed publication — can be misused to manipulate public reaction, generate funding or hide critical information.

BASED ON PFG October Newsletter

DIAGNOSTIC

- WHO enlists more COVAX participants, clears 2nd rapid test. CIDRAP
- Nigerian scientists develop cheaper and faster Covid-19 test kits. CNN
- India's new paper Covid-19 test could be a 'game changer'. BBC
- Optum Global Solutions pledges INR 2.20 crores to strengthen COVID-19 testing capacity in India
- Combining Rapid PCR and Antibody Tests Improved COVID-19 Diagnosis. JAMA
- Scientists develop extremely rapid diagnostic test for COVID-19. MedicalXpress
- FIND and BIOASTER collaborate on clinical research to assess duration of immune response in patients with COVID-19
- Millions more virus rapid tests, but are results reported?. AP
- 'Killer' cells in Ebola immunity study could help Covid research. The Guardian
- LabCorp launches COVID-19 antibody test for measuring vaccine effectiveness. Fierce Biotech
- GeneXpert for the diagnosis of COVID-19 in LMICs. The Lancet Correspondance
- New COVID-19 rapid tests a game changer for Africa. WHO Afro
- Few COVID-19 Rapid Diagnostic Tests Meet WHO Standards For Accuracy – FIND Study. Health Policy Watch
- Celltrion nabs emergency use for rapid COVID-19 test from FDA. Fierce Biotech
- Singapore firm invents coronavirus breathalyser with results in seconds. Reuters

TREATMENT

- Warp Speed's focus on vaccines may have shortchanged antibody treatments. Politico
- Lilly Seeks Emergency Use of Its Antibody Drug for COVID-19. Medscape
- EU buys more Remdesivir to treat 3,400 patients amid shortages. Reuters

Regeneron asks FDA for emergency authorization of its Covid-19 antibody therapy given to Trump last week. CNN
Regeneron REGN-COV2 monoclonal antibody reported better in (non-hospitalized) patients who lack their own antibodies to SARS-CoV-2. Science Speaks
Solidarity Therapeutics Trial produces conclusive evidence on the effectiveness of repurposed drugs for COVID-19 in record time. WHO
Gloomy COVID drug data shows why big, randomised trials matter. Reuters
NIH launches COVID-19 test of J&J, Bristol Myers and AbbVie anti-inflammatory drugs. Fierce Pharma
Blood plasma showed no benefit in Covid-19 patients in trial — a finding that could re-energize debate. STAT
Peer-Reviewed Remdesivir for the Treatment of Covid-19 — Final Report. Beigal, et al. NEJM, DOI: 10.1056/NEJMoa2007764 , Oct 8 2020.
The race to make COVID antibody therapies cheaper and more potent. Nature
Gilead Sciences Ignored WHO Evidence That Remdesivir Fails To Reduce COVID19 Mortality – In US FDA Submission For Drug's Approval. Health Policy Watch
Lilly antibody drug fails in a COVID-19 study; others go on. AP
The 'very, very bad look' of remdesivir, the first FDA-approved COVID-19 drug. Science
Gilead's Covid-19 Drug Is Mediocre. It Will Be a Blockbuster Anyway. The New York Times
RACE FOR VACCINE
Race for Covid-19 vaccine slows as regulators, top Warp Speed official tap the brakes. STAT
COVID-19 vaccine may be ready by year-end, says WHO's Tedros. Reuters
China in talks with WHO over assessing its COVID-19 vaccines for global use. Reuters
China joins WHO-backed vaccine programme COVAX rejected by Trump. Thomson Reuters
China, Republic of Korea Join COVAX Global Vaccine Pool – WHO Urges Countries To Jumpstart Vaccine Campaigns. Health Policy Watch
Coronavirus: what China's decision to join the WHO's vaccine scheme means. South China Morning Post

The future of vaccine development: 5 legacies from COVID-19. Bio Pharma Reporter
Johnson & Johnson pauses Covid vaccine trial over participant's 'unexplained illness'. The Guardian
Eli Lilly and Johnson & Johnson have paused COVID-19 vaccine trials. Why experts say that's reassuring, not frightening. USA Today
Putin Announces Approval Of A 2nd Unproven Coronavirus Vaccine. NPR
Early approval of a COVID-19 vaccine could stymie the hunt for better ones. Science
Pfizer won't apply for Covid-19 vaccine authorization before mid-November, CEO confirms. STAT
China's Inactivated COVID-19 Vaccine Candidate Is Safe and Provokes Immune Response, Say Preliminary Clinical Trial Results. Health Policy Watch
The vaccine itself is not the silver bullet,' says International Vaccine Institute. CGTN
Could certain COVID-19 vaccines leave people more vulnerable to the AIDS virus?. Science
Coronavirus Vaccine Tracker. The New York Times
Two more laboratories join CEPI's centralised network to standardise assessment of COVID-19 vaccines. CEPI
Leading US Expert Anthony Fauci: 'Cautiously Optimistic' About COVID-19 Vaccine Approval This Month Or Next . Health Policy Watch
CEPI expands global manufacturing network, reserving manufacturing capacity for more than 1 billion doses of COVID-19 vaccines. CEPI
Unprecedented vaccine trials on track to begin delivering results. Washington Post
Covid-19 vaccine trials from AstraZeneca, Johnson & Johnson to restart. STAT
Rush for results could lead to inferior Covid vaccine, say scientists. The Guardian
A Chinese Vaccine Could Save American Lives. Bloomberg
Vaccine hopes rise as Oxford jab prompts immune response among old as well as young adults. Reuters
Historic vaccine race meets harsh reality. Politico
Russia applies for WHO emergency use tag for its COVID-19 vaccine. Reuters
No news on Pfizer's Covid-19 vaccine is good news — and bad news. STAT

Manufacturing delays push Novavax's COVID-19 vax trial to end of November. Fierce Biotech
Sanofi, GSK sign agreement to make vaccine candidate available to COVAX. Homeland Preparedness News
J&J plans to test its COVID-19 vaccine in ages 12-18 soon. Reuters
VACCINE ACCES
Effort to bring coronavirus vaccines to poor countries faces obstacles. LA Times
Coronavirus vaccine 'for all' unlikely before 2022, says leading figure. The Telegraph
COVID-19 Vaccines A Global Common Good. The Lancet Comment
Expert panel recommends U.S. join international vaccine pool, contribute vaccine to low-income nations. STAT
What is COVAX and why does it matter for getting vaccines to developing nations?. The Conversation
South Africa and India urge WTO to waive IP rights, widen access to Covid-19 drugs and vaccines. STAT
Covid-19: how to prioritize worse-off populations in allocating safe and effective vaccines. BMJ
WHO boss: Vaccine allocation is political. Politico
COVID-19 vaccines: how to ensure Africa has access. Nature
IAVI, Merck KGaA, Darmstadt, Germany, and Serum Institute of India Join Forces to Develop Monoclonal Antibodies for COVID-19 and Ensure Prompt and Equitable Global Access
What China's speedy COVID vaccine deployment means for the pandemic. Nature
Eli Lilly in deal to supply COVID-19 drugs to low-income countries. Reuters
COVID-19 Crisis and WTO: Why India and South Africa's Proposal on Intellectual Property is Important. The Wire
Unitaid supports call for intellectual property waivers and action for access to COVID-19 products. UNITAID
Vaccine initiative now covers almost entire world, but not U.S. or Russia. Axios
The Indian/South African Proposal For a WTO Waiver On IP For COVID-19 Related Health Products – What It Means?. Health Policy Watch

Hundreds of advocacy groups urge WTO to waive IP rights to Covid-19 drugs and vaccines. STAT
Protecting the profits of a few could prevent vaccine access for all. The Hill
Global Covid report: young and healthy may not get vaccine until 2022, WHO says. The Guardian
Africa needs to go beyond COVAX to secure vaccine doses, experts say. Devex
What will it take to make COVID-19 vaccines globally available?. Brandeis University
Vaccine storage issues could leave 3B people without access. AP
UNICEF to stockpile over half a billion syringes by year end, as part of efforts to prepare for eventual COVID-19 vaccinations. UNICEF
WHO backs Indian proposal to ensure universal access to Covid vaccine. The Independent
Very large portion of COVID-19 vaccines likely to be manufactured in India: Gates Foundation CEO. The Hindu
Planes, trucks and ultracold boxes: Pfizer preps massive COVID-19 vaccine distribution effort. Fierce Pharma
PEER-REVIEWED ARTICLES Facilitating Access to a COVID-19 Vaccine through Global Health Law. Gostin, L et al. Sage Journal, DOI: https://doi.org/10.1177/1073110520958892 , Oct 6 2020
Gavi signs statement of intent to procure 200 million doses of Sanofi-GSK COVID-19 vaccine candidate for the COVAX Facility. GAVI
Skoll Foundation Funds Sabin Vaccine Institute, Dalberg and JSI Research & Training Institute, Inc. to Establish COVID-19 Vaccine Equity Project. Biospace
Under pressure, WHO plans COVID-19 vaccine insurance scheme for poor nations. Reuters
FUNDING and PRICES
World leaders pledge \$1B for ACT-Accelerator. Devex
GAVI providing \$150 million to poorer countries to prepare for COVID-19 vaccines. Reuters
Gavi Covax facility misses Covid-19 vaccine project funding targets, eyes cost-sharing. IB Times
COVAX Vaccine Plan Not Transparent: WHO Board Member. Code Blue

Countries pledge nearly US\$ 1 billion to support equitable access to COVID-19 vaccines. GAVI
Japan pledges US\$ 130 million to support global access to COVID-19 vaccines.
World Bank Approves \$12 Billion for COVID-19 Vaccines. World Bank
AstraZeneca says its Oxford vaccine deal allows it to add up to 20% of manufacturing costs. Reuters
GSK And Sanofi Pledge 200 Million Vaccine Doses To Covid-19 Alliance. Forbes
MSF response to Gavi's intent to purchase Sanofi-GSK COVID-19 vaccine candidate for the COVAX Facility. MSF
Italy pledges first EUR 5 million funding to CEPI to advance COVID-19 vaccine development efforts. CEPI
Rights, Transparency Central for Covid-19 Vaccines. Human Rights Watch
Activists urge 'Big Pharma' to be transparent on COVID-19 vaccine costs. Reuters
Vaccine bond sale raises \$500m to fund immunisation programmes. Financial Times
OTHERS COVID19 ISSUES: ETHICAL, POLICY DILEMAS, ACCOUNTABILITY
CEPI establishes global network of laboratories to centralise assessment of COVID-19 vaccine candidates. CEPI
Why and how do we harmonise assessment of COVID-19 vaccine trials?. CEPI
COVID-19 poised to push global response to HIV/AIDS to the fringes. The Guardian Nigeria
Moderna vaccine trial contractors fail to enroll enough minorities, prompting slowdown - sources. Reuters
Vaccine allocation and WHO reform take center stage as WHO executive board meets. Devex
In landmark move, India and South Africa propose no patents on COVID-19 medicines, tools during pandemic. MSF
He's a recruiter for a Covid-19 vaccine trial. Can he overcome communities' distrust — and his own mother's?. STAT
Moderna Makes Milestone Pledge To "Not Enforce Our Patents" On COVID-19 Vaccine Technologies During Pandemic & Issue Open Licenses Afterward. Health Policy Watch
7 looming questions about the rollout of a Covid-19 vaccine. STAT

Will Africa's best shot at a Covid-19 vaccine be enough?. Mail & Guardian
Paused: Eli Lilly monoclonal antibody study and J&J COVID-19 vaccine trials. Science Speaks
Everything You Need to Know About the ACT-Accelerator. Global Citizen
Coronavirus threatens to reverse gains in global fight against tuberculosis, WHO warns. The Telegraph
Is It Lawful and Ethical to Prioritize Racial Minorities for COVID-19 Vaccines?. JAMA
WHO vaccine drive bedevilled by familiar question: who pays if things go wrong?. Reuters
The Vaccine News That Really Matters. The Atlantic
Covid: firm secures £10m to infect young volunteers to hasten vaccine. The Guardian
U.K. to infect healthy volunteers in Covid-19 vaccine research trial. STAT
Covid-19 vaccine trial protocols released. BMJ Editorial
Will covid-19 vaccines save lives? Current trials aren't designed to tell us. BMJ
Understanding COVID-19 vaccine efficacy. Science
Opinion: COVAX and the case for multilateralism. Devex
USA joins CEPI to support the development of epidemic vaccines. CEPI
Harnessing COVID-19 Innovations Could Revolutionize TB Care. Health Policy Watch
Watch: mRNA vaccines face their first test in the fight against Covid-19. How do they work?. STAT
Virtual World Health Summit Opens In Shadow Of Virus Spread Across Europe & Debate Over Vaccine Access. Health Policy Watch
Maintaining confidentiality of emerging results in COVID-19 vaccine trials is essential. Lancet Commentary
UN agency chiefs appeal for 'open science' beyond COVID-19, citing dangers of secrecy and denial. UN News
Nigerian researchers seek funding to move Africa-centric COVID-19 vaccine to human trials. Cornell Alliance for Science
Regeneron hit by 'safety signal' for COVID-19 cocktail as data board tells pharma to stop enrolling sicker patients. Fierce Biotech
'Patient friction coefficient' can gauge the burden of participating in a clinical trial. STAT
Source: PFG October Newsletter